X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

AVEO

Closed

Aveo Pharmaceuticals Inc

15.
0 (0.00%)
Last Update: 20 Jan 2023 17:30:00
Yesterday: 15.
Day's Range: 15. - 15.
Send
When Written:
 
15
AVEO Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes targeted therapies for cancer and other diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

AVEO's lead product candidate is tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor that is being developed for the treatment of renal cell carcinoma (RCC) and other solid tumors. In addition to tivozanib, AVEO is also developing several other product candidates, including ficlatuzumab, AV-203, and AV-380.

The company has collaborations with several pharmaceutical and biotechnology companies, including Biogen, EUSA Pharma, and Novartis. AVEO's mission is to discover, develop, and commercialize targeted therapies that improve the lives of patients with cancer and other diseases.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X